Adalimumab
- PDF / 169,739 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 109 Downloads / 158 Views
1 S
Multiple sclerosis: 3 case reports In a report, three patients (2 women and 1 man) aged 26–55 years were described, who developed multiple sclerosis (MS) during treatment with adalimumab for sarcoidosis, psoriatic seronegative spondyloarthritis or recurrent bilateral intermediate uveitis [dosages and routes not stated]. A 29-year-old woman, whose medical history was notable for pulmonary, cutaneous and ocular sarcoidosis, had been receiving adalimumab for 5 months. Subsequent MRI showed sixth cranial nerve palsy with numerous lesions in the pons, medulla and periventricular and subcortical white matter. Some lesions showed gadolinium-enhancement. She fulfilled McDonalds criteria for MS, which was thought to be related to adalimumab treatment. Adalimumab was discontinued. A 26-year-old woman, whose medical history was notable for Hashimoto thyroiditis, coeliac disease and psoriatic seronegative spondyloarthritis, had been receiving adalimumab for 36 months. She subsequently presented with lower-limb numbness. MRI showed acute myelitis and typical periventricular lesions. She fulfilled McDonalds criteria for MS, which was thought to be related to adalimumab treatment. Adalimumab was discontinued. A 55-year-old man, who had recurrent bilateral intermediate uveitis, had been receiving treatment with adalimumab for 14 months. He subsequently developed MS (he fulfilled McDonalds criteria for MS), which was thought to be related to adalimumab treatment. Adalimumab was discontinued [times to reactions onset and outcomes not stated]. Ciano Petersen NL, et al. Anti-tumour necrosis factor-alpha related demyelinating diseases. cause, trigger or coincidence. European Journal of Neurology 27 (Suppl. 1): 975 803498565 abstr. EPO2339, May 2020. Available from: URL: http://doi.org/10.1111/ene.14200 [abstract]
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
